IL236647A0 - Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk - Google Patents

Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Info

Publication number
IL236647A0
IL236647A0 IL236647A IL23664715A IL236647A0 IL 236647 A0 IL236647 A0 IL 236647A0 IL 236647 A IL236647 A IL 236647A IL 23664715 A IL23664715 A IL 23664715A IL 236647 A0 IL236647 A0 IL 236647A0
Authority
IL
Israel
Prior art keywords
biguanides
statins
compositions
further agents
cardiometabolic risk
Prior art date
Application number
IL236647A
Other languages
Hebrew (he)
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of IL236647A0 publication Critical patent/IL236647A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL236647A 2012-07-11 2015-01-11 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk IL236647A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders
PCT/US2013/050142 WO2014011926A1 (en) 2012-07-11 2013-07-11 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Publications (1)

Publication Number Publication Date
IL236647A0 true IL236647A0 (en) 2015-02-26

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236647A IL236647A0 (en) 2012-07-11 2015-01-11 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk

Country Status (9)

Country Link
EP (1) EP2872127A1 (en)
JP (2) JP2015522080A (en)
CN (1) CN104780915A (en)
AR (1) AR091739A1 (en)
AU (1) AU2013290100A1 (en)
CA (1) CA2878625A1 (en)
HK (1) HK1210825A1 (en)
IL (1) IL236647A0 (en)
WO (1) WO2014011926A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906582A (en) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (en) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Therapeutic uses of empagliflozin.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (en) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (en) 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (en) 1993-04-19 1995-07-13 Cripdom Microcapsules of acetylsalicylic acid with controlled release.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
FR2725623A1 (en) 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
HUP0000838A3 (en) 1997-04-15 2001-04-28 Csir Extract containing steroid-glucosid, process for its isolation and synthesis, pharmaceutical composition containing it having appetite suppressant activity
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (en) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20030113810A1 (en) 2000-02-18 2003-06-19 Alan Wise Novel assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
JP4360915B2 (en) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム G protein-coupled receptor GPR43 ligand and use thereof
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (en) 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2004038421A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003273994A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CN1413582A (en) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
JP4654038B2 (en) 2002-12-18 2011-03-16 ジボダン エス エー Chimeric alpha Q-gustducin G protein
EP1597588A1 (en) 2003-02-17 2005-11-23 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (en) 2003-02-26 2004-09-09 Basf Ag Enzymatic production of (meth) acrylic acid esters
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US20070093545A1 (en) 2003-11-21 2007-04-26 Arena Pharmaceuticals, Inc. 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof
RU2006126978A (en) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) 3- (4-BENZYLOXYPHENYL) PROPANIC ACID DERIVATIVES
JP4855777B2 (en) 2003-12-26 2012-01-18 武田薬品工業株式会社 Phenylpropanoic acid derivatives
WO2005087710A1 (en) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
WO2005095338A1 (en) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
WO2005102311A1 (en) 2004-04-20 2005-11-03 Deutsches Institut für Ernährungsforschung Agonists of a bitter taste receptor and uses thereof
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Therapeutic agent for diabetes
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
CA2580130A1 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. Gpr43 and modulators thereof for the treatment of metabolic-related disorders
US20080021069A1 (en) 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
CA2584224A1 (en) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
US7829299B2 (en) 2004-11-18 2010-11-09 Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
CA2593858A1 (en) 2005-01-31 2006-08-10 Min Ge Antidiabetic bicyclic compounds
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
EP1878734A4 (en) 2005-04-28 2010-02-17 Ajinomoto Kk Novel lactam compound
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
AU2006262399A1 (en) 2005-06-22 2007-01-04 Senomyx, Inc. Identification of human T2R recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators
EP1907422A1 (en) 2005-07-28 2008-04-09 Nestec S.A. Fat taste receptors and their methods of use
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924709A1 (en) 2005-08-10 2008-05-28 Arena Pharmaceuticals, Inc. Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist
JP4932724B2 (en) 2005-09-02 2012-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Screening method of substances useful for diseases using GPR120 and phospholipase
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (en) 2006-01-11 2007-08-23 Canon Inc Information processing apparatus, control method thereof, program and recording medium
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
MX2008012814A (en) 2006-04-06 2008-10-17 Prosidion Ltd Heterocyclic gpcr agonists.
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
EP2369341A3 (en) 2006-04-11 2012-01-04 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5271895B2 (en) 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Antidiabetic bicyclic compounds
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited Fused cyclic compounds
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (en) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 Medicinal composition for promoting enterogastric peristalsis
JP2009543805A (en) 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション Indoline derivatives and GPR119 agonists
CA2660464A1 (en) 2006-08-17 2008-02-21 Unilever Plc Processes for production of hoodia plant extracts containing steroidal glycosides
CA2661593A1 (en) 2006-08-24 2008-02-28 Unilever Plc Process for preparing a composition comprising steroidal glycosides
JP2010501630A (en) 2006-08-30 2010-01-21 ビオヴィトルム・アクチボラゲット（プブリクト） Pyrimidine compounds for treating GPR119 related disorders
WO2008030429A2 (en) 2006-09-05 2008-03-13 Senomyx, Inc. Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
JP2010508268A (en) 2006-10-31 2010-03-18 メルク エンド カムパニー インコーポレーテッド Antidiabetic bicyclic compound
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (en) * 2006-11-16 2008-07-08 Walter Junior Santos medicine "rosuvastatin + metformin" in combination form for cardiovascular disease
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (en) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 Enteric medicinal composition for treating diabetes and preparation method thereof
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
US8058312B2 (en) * 2007-01-29 2011-11-15 Hanall Biopharma Co., Ltd. N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CN101663298A (en) 2007-02-22 2010-03-03 Irm责任有限公司 Thiazole derivatives as modulators of g protein-coupled receptors
AU2008222812B2 (en) 2007-03-08 2012-03-22 Irm Llc Compounds and compositions as modulators of GPR119 activity
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2148679A1 (en) 2007-04-20 2010-02-03 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
JP2010524941A (en) 2007-04-20 2010-07-22 シェーリング コーポレイション Pyrimidinone derivatives and methods for their use
CA2684633A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
JP5420400B2 (en) 2007-04-26 2014-02-19 国立大学法人京都大学 G protein-coupled receptor agonist
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
US8309534B2 (en) 2007-05-15 2012-11-13 Medical College Of Georgia Research Institute, Inc. Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancer
KR20100051814A (en) 2007-07-17 2010-05-18 브리스톨-마이어스 스큅 컴퍼니 Method for modulating gpr119 g protein-coupled receptor and selected compounds
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033078A2 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
WO2009038204A1 (en) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
KR20100090249A (en) 2007-10-10 2010-08-13 암젠 인크 Substituted biphenyl gpr 40 modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
JP2011500727A (en) 2007-10-22 2011-01-06 シェーリング コーポレイション Bicyclic heterocyclic derivatives and their use as modulators of GPR119 activity
JP2011016722A (en) 2007-10-23 2011-01-27 Astellas Pharma Inc Thiazolidinedione compound
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
US20100316736A1 (en) 2007-10-24 2010-12-16 Desert Labs Agriculture Cooperative Association Ltd. Appetite suppressant
AU2008319418B2 (en) 2007-10-29 2013-08-15 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN101918014B (en) 2008-01-29 2012-06-20 中森制药株式会社 Medicinal composition
AU2009217359B2 (en) 2008-02-22 2011-09-01 Irm Llc Compounds and compositions as modulators of GPR119 activity
US20110172244A1 (en) 2008-02-22 2011-07-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
CA2716330A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CL2009000782A1 (en) 2008-03-31 2010-04-30 Metabolex Inc Method comprising a substituted oxymethylene aryl derivative compound, dpp-iv inhibitors; and its use in the treatment of diabetes and lowering of triglycerides, among other diseases.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN102056900A (en) 2008-04-07 2011-05-11 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
WO2009125804A1 (en) 2008-04-09 2009-10-15 武田薬品工業株式会社 Screening method
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
WO2009151542A2 (en) 2008-05-27 2009-12-17 Duke University Nicotinic acid receptor ligands
CN101695575A (en) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid
US20110065739A1 (en) 2008-06-02 2011-03-17 Makoto Ishikawa Novel isoxazole drivative
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
BRPI0914891A2 (en) 2008-06-20 2015-11-24 Metabolex Inc aril gpr119 agonists and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CN102137844B (en) 2008-07-11 2013-05-22 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
JP2011528365A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives as GPR119 modulators and methods for their use
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN105152919A (en) 2008-07-28 2015-12-16 赛丹思科大学 Compounds for the treatment of metabolic diseases
EP2311822A4 (en) 2008-08-01 2011-08-31 Nippon Chemiphar Co Gpr119 agonist
WO2010022529A1 (en) 2008-08-29 2010-03-04 Givaudan Sa Methods to identify modulators
ES2550077T3 (en) 2008-08-29 2015-11-04 Suntory Holdings Limited New epigallocatechin gallate tetramer and vascular endothelial function enhancer comprising the same
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011004125A (en) 2008-10-21 2011-05-19 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof.
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
WO2010074271A1 (en) 2008-12-26 2010-07-01 武田薬品工業株式会社 Therapeutic agent for diabetes
CN102272129B (en) 2009-01-03 2014-10-08 静冈县公立大学法人 Sulfated c-glycoside, method for isolating same and method for synthesizing same
JPWO2010084944A1 (en) 2009-01-22 2012-07-19 田辺三菱製薬株式会社 Novel pyrrolo [2,3-d] pyrimidine compounds
CA2749663A1 (en) 2009-01-23 2010-07-29 Hubert B. Josien Pentafluorosulpholane-containing antidiabetic compounds
US20110312967A1 (en) 2009-01-23 2011-12-22 Schering Corporation Bridged and fused antidiabetic compounds
CA2749930A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
US8410089B2 (en) 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012136438A (en) 2009-04-22 2012-07-19 Astellas Pharma Inc Tetrazole compound
CN102421739A (en) 2009-04-22 2012-04-18 安斯泰来制药株式会社 Carboxylic acid compound
JP2012136439A (en) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd Diazaspiroalkane derivative
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
JP2012526097A (en) 2009-05-08 2012-10-25 ファイザー・インク GPR119 regulator
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
US20120172351A1 (en) 2009-06-09 2012-07-05 Nobuyuki Negoro Novel fused cyclic compound and use thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AR077638A1 (en) 2009-07-15 2011-09-14 Lilly Co Eli COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
WO2011012298A1 (en) 2009-07-28 2011-02-03 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2474540A4 (en) 2009-08-31 2013-03-13 Nippon Chemiphar Co Gpr119 agonist
MY158504A (en) 2009-09-01 2016-10-14 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
CA2772188A1 (en) 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
US20110082156A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
US20110082202A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
EP2486005B1 (en) 2009-10-06 2014-06-18 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
CN102686579A (en) 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
WO2011051966A2 (en) * 2009-10-12 2011-05-05 Ipca Laboratories Limited Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
WO2011050163A1 (en) 2009-10-21 2011-04-28 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
JPWO2011055770A1 (en) 2009-11-06 2013-03-28 武田薬品工業株式会社 Fused heterocyclic compounds
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
WO2011061679A1 (en) 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
RU2012127779A (en) 2009-12-04 2014-01-20 Колгейт-Палмолив Компани COMPOSITION FOR CARE OF THE ORAL CAVITY CONTAINING EXTRACTS FROM Garcinia mangostana L., AND RELATED METHODS
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
RS56751B1 (en) 2009-12-18 2018-04-30 Ogeda Sa Pyrrolidine carboxylic acid derivatives as agonists of g-protein coupled receptor 43 (gpr43), pharmaceutical composition and methods for use in treating metabolic disorders
JP2013047188A (en) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119 agonist
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
KR20120130104A (en) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 agonist
CN101785763B (en) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102918027A (en) 2010-04-06 2013-02-06 艾尼纳制药公司 Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
BR112012028445A2 (en) 2010-05-06 2016-07-19 Bristol Myers Squibb Co bicyclic heteroaryl compounds as gpr119 modulators
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
WO2011138427A2 (en) 2010-05-07 2011-11-10 Boehringer Ingelheim International Gmbh Pyridazinones as gpr119 agonists
JP2013530947A (en) 2010-05-17 2013-08-01 アレイ バイオファーマ、インコーポレイテッド Piperidinyl-substituted lactams as GPR119 modulators
WO2011145718A1 (en) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 Novel pyrrolo[2,3-d]pyrimidine compound
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
KR20120011357A (en) 2010-07-23 2012-02-08 현대약품 주식회사 Substituted pyridinone derivatives and methods for manufacturing the same
MA34474B1 (en) 2010-07-23 2013-08-01 Connexios Life Sciences Pvt Ltd AGONISTS OF GPR40
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
KR20130099970A (en) 2010-09-17 2013-09-06 어레이 바이오파마 인크. Piperidinyl-substituted lactams as gpr119 modulators
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
CN102432598A (en) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
SG188547A1 (en) 2010-10-08 2013-04-30 Cadila Healthcare Ltd Novel gpr 119 agonists
JP2014001144A (en) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Gpr119 agonist
CN101978956B (en) * 2010-10-13 2012-03-28 北京京丰制药有限公司 Metformin hydrochloride enteric-coated tablets and preparation method thereof
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
EP2643310A1 (en) 2010-11-23 2013-10-02 Pfizer Inc 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
WO2012077655A1 (en) 2010-12-07 2012-06-14 塩野義製薬株式会社 Spiro derivative having gpr119 agonist activity
UY33805A (en) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ? Dihydrobenzofuranyl-piperidinyl, aza-dihydrobenzofuranylpiperidinyl and diaza-dihydrobenzofuranyl-piperidinyl derivatives, pharmaceutical compositions containing them and uses thereof?
CN103328482A (en) 2011-01-03 2013-09-25 韩美药品株式会社 New bicyclic compound for modulating G protein-coupled receptors
WO2012098217A1 (en) 2011-01-21 2012-07-26 Boehringer Ingelheim International Gmbh Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
TW201309639A (en) 2011-02-17 2013-03-01 Lg Life Sciences Ltd Oxime derivatives as GPR119 agonists
WO2012123449A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499467B2 (en) 2011-04-08 2016-11-22 Caldan Therapeutics Limited Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
BR112013027883A2 (en) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd new 3-hydroxyisothiazole 1-oxide derivative
WO2012147516A1 (en) 2011-04-28 2012-11-01 持田製薬株式会社 Cyclic amide derivative
KR101401496B1 (en) 2011-05-12 2014-06-11 한국화학연구원 Thienopyrimidine derivatives, pharmaceutically acceptable salt thereof preparation method thereof and pharmaceutical composition for prevention or treatment of diabetes-related disease containing the same as an active ingredient
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2718288B1 (en) 2011-06-09 2015-03-11 Boehringer Ingelheim International GmbH Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
JP2014159376A (en) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd Azaspiroalkane compound
WO2013011402A1 (en) 2011-07-15 2013-01-24 Pfizer Inc. Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (en) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 Metformin hydrochloride enteric-coated tablet

Also Published As

Publication number Publication date
CN104780915A (en) 2015-07-15
AU2013290100A1 (en) 2015-01-29
CA2878625A1 (en) 2014-01-16
WO2014011926A1 (en) 2014-01-16
JP2018087214A (en) 2018-06-07
JP2015522080A (en) 2015-08-03
HK1210825A1 (en) 2016-05-06
EP2872127A1 (en) 2015-05-20
AR091739A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL238959A (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL239568A0 (en) Antimicrobial compositions
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof
PT2825699T (en) Fibrous composition
HK1212625A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder -cxcl9-cxcl10-cxcl11-cxcl13-cxcr3 -cxcr5
IL235585A0 (en) Ha binding agents, compositions comprising same and uses thereof
IL236463A0 (en) Bifluorodioxalane-amino-benzimidazole compounds, compositions comprising same, processes for producing same and uses thereof
HK1210825A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
IL233824A (en) 1h-indazole-3-carboxamide compounds, compositions comprising them and uses thereof
HK1212156A1 (en) Antimicrobial composition
HK1216250A1 (en) 8-hydroxy-dihydroergotamine compounds and compositions 8--
IL236712A0 (en) Di-and tri-heteroaryl derivatives, compositions comprising same and uses thereof
HK1206266A1 (en) Methods and compositions for the prevention and treatment neuropathy
IL280316B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237542B (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237540A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
IL237538A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
EP2838365A4 (en) Antimicrobial compositions and uses thereof
EP2802565A4 (en) Compounds, compositions and associated methods comprising 3-aryl quinolines
IL237539A0 (en) Bolaamphiphilic compounds, compositions and uses thereof
ZA201408903B (en) Antimicrobial composition